

Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab

Information for the public

Published: 13 May 2020

www.nice.org.uk

Obinutuzumab (Gazyvaro) with bendamustine, then obinutuzumab alone, is available on the NHS. It is a possible treatment for people with follicular lymphoma that has not responded to therapy with rituximab or has progressed up to 6 months after it.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Lymphoma Action](#), 0808 808 5555
- [Leukaemia Care](#), 08088 010 444
- [Blood Cancer UK](#), 0808 2080 888
- [Macmillan Cancer Support](#), 0808 808 0000
- [Cancer Research UK Patient Information](#), 0808 800 4040

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3783-7